388 related articles for article (PubMed ID: 15630452)
1. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
[TBL] [Abstract][Full Text] [Related]
2. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
[TBL] [Abstract][Full Text] [Related]
3. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.
Zhu T; Muthui D; Holte S; Nickle D; Feng F; Brodie S; Hwangbo Y; Mullins JI; Corey L
J Virol; 2002 Jan; 76(2):707-16. PubMed ID: 11752161
[TBL] [Abstract][Full Text] [Related]
4. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
6. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
7. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
8. Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo.
Kulkosky J; Sullivan J; Xu Y; Malin-Markham A; Otero M; Calarota S; Zielinski J; Culnan DM; Pomerantz RJ
Virology; 2003 Sep; 314(2):617-29. PubMed ID: 14554089
[TBL] [Abstract][Full Text] [Related]
9. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
Kulkosky J; Culnan DM; Roman J; Dornadula G; Schnell M; Boyd MR; Pomerantz RJ
Blood; 2001 Nov; 98(10):3006-15. PubMed ID: 11698284
[TBL] [Abstract][Full Text] [Related]
10. Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.
Margolis DM; Archin NM
Infect Disord Drug Targets; 2006 Dec; 6(4):369-76. PubMed ID: 17168802
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART.
Otero M; Nunnari G; Leto D; Sullivan J; Wang FX; Frank I; Xu Y; Patel C; Dornadula G; Kulkosky J; Pomerantz RJ
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1097-103. PubMed ID: 14709246
[TBL] [Abstract][Full Text] [Related]
12. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
[TBL] [Abstract][Full Text] [Related]
13. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death.
Rydze RT; Bhattarai N; Stapleton JT
Antivir Ther; 2012; 17(7):1271-9. PubMed ID: 22951385
[TBL] [Abstract][Full Text] [Related]
14. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
[TBL] [Abstract][Full Text] [Related]
16. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
17. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
[TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
[TBL] [Abstract][Full Text] [Related]
19. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Finzi D; Hermankova M; Pierson T; Carruth LM; Buck C; Chaisson RE; Quinn TC; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho DD; Richman DD; Siliciano RF
Science; 1997 Nov; 278(5341):1295-300. PubMed ID: 9360927
[TBL] [Abstract][Full Text] [Related]
20. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
Siliciano JD; Siliciano RF
J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
